NEW YORK – Foundation Medicine said on Wednesday that it has signed a non-exclusive licensing agreement with TwinStrand Biosciences for a sequencing-based technology for rare mutation detection.
The agreement covers two foundational patent families from TwinStrand, a University of Washington spinout based in Seattle.